Jpmorgan Chase & CO Revolution Medicines, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RVMD
# of Institutions
266Shares Held
161MCall Options Held
260KPut Options Held
620K-
Vanguard Group Inc Valley Forge, PA14.9MShares$846 Million0.01% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$761 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA11.4MShares$647 Million0.09% of portfolio
-
Farallon Capital Management LLC San Francisco, CA11.3MShares$642 Million2.58% of portfolio
-
Baker Bros. Advisors LP New York, NY7.57MShares$430 Million3.67% of portfolio
About Revolution Medicines, Inc.
- Ticker RVMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,697,600
- Market Cap $4.98B
- Description
- Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...